These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Somatofugal axonal atrophy precedes development of axonal degeneration in acrylamide neuropathy. Gold BG; Griffin JW; Price DL Arch Toxicol; 1992; 66(1):57-66. PubMed ID: 1580795 [TBL] [Abstract][Full Text] [Related]
7. Acrylamide induces early morphologic reorganization of the neuronal cell body. Sterman AB Neurology; 1982 Sep; 32(9):1023-6. PubMed ID: 7202150 [TBL] [Abstract][Full Text] [Related]
8. Comparison of subchronic neurotoxicity of 2-hydroxyethyl acrylate and acrylamide in rats. Moser VC; Anthony DC; Sette WF; MacPhail RC Fundam Appl Toxicol; 1992 Apr; 18(3):343-52. PubMed ID: 1597260 [TBL] [Abstract][Full Text] [Related]
9. A correlative neurobehavioral-morphological model of acrylamide neuropathy. Sterman AB; Sheppard RC Neurobehav Toxicol Teratol; 1983; 5(1):151-9. PubMed ID: 6304547 [TBL] [Abstract][Full Text] [Related]
10. Effect of acrylamide and related compounds on glycolytic enzymes of rat brain. Tanii H; Hashimoto K Toxicol Lett; 1985 Jul; 26(1):79-84. PubMed ID: 3161219 [TBL] [Abstract][Full Text] [Related]
13. Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathies. Spencer PS; Schaumburg HH J Neuropathol Exp Neurol; 1977; 36(2):300-20. PubMed ID: 190358 [TBL] [Abstract][Full Text] [Related]
14. Acrylamide neuropathy in the rat: effects on energy metabolism in sciatic nerve. Brimijoin WS; Hammond PI Mayo Clin Proc; 1985 Jan; 60(1):3-8. PubMed ID: 2981375 [TBL] [Abstract][Full Text] [Related]
15. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. IV. In vitro analysis of transport following acrylamide and 2,5-hexanedione. Sickles DW Toxicol Lett; 1992 Jul; 61(2-3):199-204. PubMed ID: 1641866 [TBL] [Abstract][Full Text] [Related]
16. Subchronic toxicity of acrylamide administered to rats in the drinking water followed by up to 144 days of recovery. Burek JD; Albee RR; Beyer JE; Bell TJ; Carreon RM; Morden DC; Wade CE; Hermann EA; Gorzinski SJ J Environ Pathol Toxicol; 1980 Nov; 4(5-6):157-82. PubMed ID: 7217844 [TBL] [Abstract][Full Text] [Related]
17. Effect of oral CDP-choline on acrylamide-induced lesion. Agut J; Font E; Sacristán A; Ortiz JA Arzneimittelforschung; 1983; 33(7A):1029-33. PubMed ID: 6684458 [TBL] [Abstract][Full Text] [Related]
18. Nervous system degeneration produced by acrylamide monomer. Spencer PS; Schaumburg HH Environ Health Perspect; 1975 Jun; 11():129-33. PubMed ID: 170076 [TBL] [Abstract][Full Text] [Related]
19. The influence of systemic factors on acrylamide-induced changes in brain, nerve, and other tissues. Lapin EP; Maker HS; Weissbarth S; Weiss C; Lehrer GM J Neurosci Res; 1984; 11(4):395-404. PubMed ID: 6086944 [TBL] [Abstract][Full Text] [Related]
20. Acrylamide neuropathy: changes in the composition of proteins of fast axonal transport resemble those observed in regenerating axons. Bisby MA; Redshaw JD J Neurochem; 1987 Mar; 48(3):924-8. PubMed ID: 2433402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]